The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
AACR 2021 | REGINA: regorafenib, nivolumab and short-course radiotherapy for rectal cancer
Giacomo Bregni, MD, Jules Bordet Institute, Brussels, Belgium, gives an overview of the Phase II REGINA trial (NCT04503694) which is investigating the use of regorafenib in combination with nivolumab and short-course radiotherapy in patients with intermediate-risk, stage II-III rectal cancer. This interview took place at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021.
